457
Participants
Start Date
July 22, 2019
Primary Completion Date
April 19, 2023
Study Completion Date
December 29, 2023
Tislelizumab
200 mg administered intravenously on Day 1 of each 21-day cycle
Cisplatin
75 mg/m² was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of two hours. Treatment with cisplatin was discontinued starting in Cycle 5 and beyond.
Carboplatin
An area under the curve (AUC) of 5 mg/mL/min was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of 15 to 60 minutes. Treatment with carboplatin was discontinued starting in Cycle 5 and beyond.
Etoposide
100 mg/m² was administered intravenously from Day 1 to Day 3 of each 21-day cycle, infused over a duration of 60 minutes. Treatment with etoposide was discontinued starting in Cycle 5 and beyond.
Placebo
200 mg was administered intravenously on Day 1 of each 21-day cycle to match tislelizumab.
Peking University Third Hospital, Beijing
China Japan Friendship Hospital, Beijing
Beijing Cancer Hospital, Beijing
Beijing Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Chinese Pla General Hospital, Beijing
Peking University International Hospital, Beijing
The First Hospital of China Medical University, Shenyang
Liaoning Cancer Hospital and Institute, Shenyang
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Chest Hospital, Shanghai
Shanghai Pulmonary Hospital, Shanghai
General Hospital of Eastern Theater Command, Nanjing
Nanjing Chest Hospital, Nanjing
The First Affiliated Hospital of Soochow University, Suzhou
The Second Hospital of Anhui Medical University, Hefei
Jinan Central Hospital, Jinan
Shandong Cancer Hospital, Jinan
Yantai Yuhuangding Hospital, Yantai
The Affiliated Hospital of Qingdao University Branch South, Qingdao
Tianjin Medical University General Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Fujian Medical University Union Hospital, Fuzhou
Fujian Cancer Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Daping Hospital, Third Military Medical University, Chongqing
Changsha Central Hospital, Changsha
Xiangya Hospital of Central South University, Changsha
Hunan Cancer Hospital, Changsha
Wuhan Central Hospital, Wuhan
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Cancer Center of Guangzhou Medical University, Guangzhou
Guangdong Provincial Peoples Hospital, Guangzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning
Affiliated Hospital of Guilin Medical University, Guilin
Sichuan Cancer Hospital and Institute, Chengdu
West China Hospital, Sichuan University, Chengdu
Yunnan Cancer Hospital, Kunming
Shaanxi Provincial Cancer Hospital, Xi'an
The First Affiliated Hospital of Xian Jiaotong University, Xi'an
The First Hospital of Lanzhou University, Lanzhou
Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi
Lead Sponsor
BeiGene
INDUSTRY